Sotatercept in High-Risk Pulmonary Arterial Hypertension: A Landmark Advance in Patient Outcomes

Highlights

• Sotatercept, when added to standard therapy, dramatically lowers the risk of death, lung transplantation, or hospitalization in patients with advanced, high-risk pulmonary arterial hypertension (PAH).
• The ZENITH phase 3 trial shows a hazard ratio of 0.24 for the composite primary endpoint, signaling significant clinical benefit.
• Sotatercept’s efficacy extends to delaying clinical worsening and improving functional outcomes in both intermediate and high-risk PAH populations.
• Adverse events, while notable (epistaxis, telangiectasia), were generally manageable and did not outweigh the clinical benefits.

Clinical Background and Disease Burden